Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options
Authors:
- 13 November 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 29 (10) , 1841-1847
Abstract
Sarcoidosis is a multisystem granulomatous disease of unknown aetiology characterized by the presence of noncaseating granulomas. It may affect any organ including the kidney. A disordered calcium metabolism is most often responsible for the development of renal failure. Granulomatous interstitial nephritis is the most typical histological finding, but it rarely leads to renal insufficiency. Since development of renal insufficiency in sarcoidosis is uncommon, we lack large (randomized) trials concerning the treatment of this disorder. We gather most information from case reports and small series. Our knowledge of pulmonary sarcoidosis is more comprehensive. It is, however, impossible to treat renal manifestations identically because some of the drugs used in pulmonary sarcoidosis are nephrotoxic. Moreover, renal sarcoidosis is a specific entity with its own characteristics and response to therapy. A guideline for treatment is currently missing. Based on a review of the literature, we present an overview of the different treatment options to promote a more uniform and scrutinized approach of this disease. Hypercalcaemia and hypercalciuria can be treated with corticosteroids, (hydroxy)chloroquine or ketoconazole. Preventive measures play a supportive role. In granulomatous interstitial nephritis, glucocorticoids are the standard of care. In patients with failure of or a contraindication to corticosteroids or in those patients who need a high maintenance dose of corticosteroids, azathioprine or mycophenolate mofetil can be used. TNF-alpha inhibitors are useful in case of steroid-resistant sarcoidosis or in patients who develop severe steroid toxicity. With increasing insight in the pathogenesis of sarcoidosis, other immunosuppressive drugs have been proposed, but more research is necessary before their routine use can be advocated.Keywords
This publication has 31 references indexed in Scilit:
- Refractory multisystem sarcoidosis responding to infliximab therapyClinical Rheumatology, 2012
- Diagnostic utility of kidney biopsy in patients with sarcoidosis and acute kidney injuryInternational Journal of Nephrology and Renovascular Disease, 2011
- Bone Health Issues in SarcoidosisCurrent Rheumatology Reports, 2011
- Agents anti-TNFα et sarcoïdoseLa Revue de Médecine Interne, 2010
- Renal Transplantation in Patients with SarcoidosisClinical Journal of the American Society of Nephrology, 2010
- Hypercalcemia and soft tissue calcification owing to sarcoidosis: The sunlight-cola connectionJournal of Bone and Mineral Research, 2010
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritisArthritis Care & Research, 2008
- Diabetic and endocrine emergenciesPostgraduate Medical Journal, 2007
- Isolated renal sarcoidosis: a rare presentation of a rare disease treated with infliximabClinical Rheumatology, 2006
- Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetilPediatric Nephrology, 2005